Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Obesity · Type 2 diabetes

NovoThirteen

NovoThirteen clinical programs — 94 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Bagsværd, JP HQ
PMDA registrant Type
Company details
Status
Public
HQ
Bagsværd, JP
Programs
94
Drugs
67
Patents
0
All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

NovoThirteen projects

94 ClinicalTrials.gov programs sponsored by NovoThirteen.

NovoThirteen has 94 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

94 programs

Clinical programs

Page 2 of 2

  1. NN9388-7700

    NovoThirteen

    Chronic Kidney Disease, Type 2 diabetes

    phase 2 small molecule active

    1 trial

  2. NN9388-7864

    NovoThirteen

    Type 2 diabetes and painful diabetic peripheral neuropathy

    phase 2 small molecule active

    1 trial

  3. NN9490-7678

    NovoThirteen

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  4. NN9500-4656

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  5. NN9500-7730

    NovoThirteen

    alcohol-related liver disease

    phase 2 small molecule active

    1 trial

  6. NN9541-7841

    NovoThirteen

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

    phase 2 small molecule active

    1 trial

  7. NN9662-8160

    NovoThirteen

    type 2 diabetes

    phase 2 small molecule active

    1 trial

  8. etavopivat B 10041, etavopivat B 10042

    NovoThirteen

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  9. A research study of a new medicine (NNC0650-0013) in healthy men

    NovoThirteen

    Weight management, Diabetes mellitus type 2; healthy subjects

    phase 1 other active

    1 trial

  10. A study of how CagriSema works on appetite in people with excess body weight

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  11. Investigating how NNC0487-0111 regulates insulin in adults with type 2 diabetes

    NovoThirteen

    Type 2 Diabetes

    phase 1 other active

    1 trial

  12. NN1436-7615

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

  13. NN1471-5026

    NovoThirteen

    Diabetes mellitus type 2

    phase 1 other active

    1 trial

  14. NN1471-7712

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  15. NN1644-7794

    NovoThirteen

    Type 1 diabetes mellitus

    phase 1 other active

    1 trial

  16. NN1644-8194

    NovoThirteen

    Diabetes type 1

    phase 1 other active

    1 trial

  17. NN1679-8505

    NovoThirteen

    Healthy participants and participants with type 2 diabetes

    phase 1 other active

    1 trial

  18. NN6019-7853

    NovoThirteen

    transthyretin amyloid amyloidosis cardiomyopathy (ATTR-CM)

    phase 1 other active

    1 trial

  19. NN6022-7683

    NovoThirteen

    Cardiometabolic diseases

    phase 1 other active

    1 trial

  20. NN6497-8309

    NovoThirteen

    Type I diabetes

    phase 1 other active

    1 trial

  21. NN6497-8316

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  22. NN6537-7650

    NovoThirteen

    Heart Failure

    phase 1 other active

    1 trial

  23. NN6582-4838

    NovoThirteen

    Healthy Volunteers

    phase 1 other active

    1 trial

  24. NN6705-8141

    NovoThirteen

    Cardiometabolic diseases with an inflammatory component

    phase 1 other active

    1 trial

  25. NN6706-8230

    NovoThirteen

    Healthy volunteers, treatment for heart failure

    phase 1 other active

    1 trial

  26. NN7442-7582

    NovoThirteen

    Prophylaxis and on-demand treatment respectively in patients with haemophilia A with or without FVIII inhibitors.

    phase 1 other active

    1 trial

  27. NN7442-8454

    NovoThirteen

    Haemophilia A with or without inhibitors. Proposed indication under development: prevention of bleeding and long-term prophylaxis in patients with haemophilia A, irrespective of inhibitor status or severity.

    phase 1 other active

    1 trial

  28. NN7614-7656

    NovoThirteen

    Hereditary haemochromatosis (HH) type 1

    phase 1 other active

    1 trial

  29. NN9388-7782

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

  30. NN9490-7611

    NovoThirteen

    Obesity and Diabetes mellitus Typ 2

    phase 1 other active

    1 trial

  31. NN9490-8151

    NovoThirteen

    Participants with obesity, but otherwise healthy

    phase 1 other active

    1 trial

  32. NN9490-8152

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  33. NN9490-8156

    NovoThirteen

    hepatic impairment

    phase 1 other active

    1 trial

  34. NN9541-4922

    NovoThirteen

    Healthy postmenopausal females (Type 2 Diabetes)

    phase 1 other active

    1 trial

  35. NN9541-4923

    NovoThirteen

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  36. NN9541-7760

    NovoThirteen

    Type 2 diabetes mellitus

    phase 1 other active

    1 trial

  37. NN9541-8116

    NovoThirteen

    Obesity, Type 2 Diabetes with either overweight or obesity

    phase 1 other active

    1 trial

  38. NN9733-8133

    NovoThirteen

    Healthy Participants and Participants with type 2 diabetes

    phase 1 other active

    1 trial

  39. NN9833-8285

    NovoThirteen

    obesity

    phase 1 other active

    1 trial

  40. NN9833-8421

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  41. NN9838-4695

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  42. NN9838-8411

    NovoThirteen

    Obesity, CCI, CCI

    phase 1 other active

    1 trial

  43. The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

    NovoThirteen

    Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).

    phase 1 other active

    1 trial

  44. NN1436-7727

    NovoThirteen

    Type 2 diabetes

    approved small molecule active

    1 trial

  45. NN9536-7752

    NovoThirteen

    Obesity

    approved small molecule active

    1 trial

  46. NN9838-4968

    NovoThirteen

    Obesity and T2D

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does NovoThirteen have?

94 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.